Non-Hodgkin Lymphoma

First human trial of ISS immunotherapy and rituximab initiated

Published in Blood Weekly, April 25th, 2002

Dynavax Technologies Corp., a privately held biopharmaceutical company, announced it has initiated a phase I clinical study with Dana-Farber/Partners Cancer Care to evaluate the safety and tolerability of a new cancer therapy combining for the first time a proprietary immunostimulatory DNA sequence (ISS) with a monoclonal antibody therapy for the treatment of B-cell non-Hodgkin lymphoma.

Dynavax said that the objective of the study is to produce data on the compound's pharmacokinetics and on biological response markers and that it plans to use the data to select an appropriate dosage for further development of the compound in a blinded, phase II placebo-controlled...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2002-04-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry